Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 5
2002 4
2003 1
2008 1
2009 1
2011 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group; Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International Collaboration of Trialists, et al. J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502557 Free PMC article. Clinical Trial.
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ; FinnBladder Group. Järvinen R, et al. Eur Urol. 2015 Oct;68(4):611-7. doi: 10.1016/j.eururo.2015.02.022. Epub 2015 Mar 5. Eur Urol. 2015. PMID: 25748117 Clinical Trial.
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R, Kaasinen E, Sankila A, Rintala E; FinnBladder Group. Järvinen R, et al. Eur Urol. 2009 Aug;56(2):260-5. doi: 10.1016/j.eururo.2009.04.009. Epub 2009 Apr 16. Eur Urol. 2009. PMID: 19395154
Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T, Järvinen R, Liukkonen T, Rintala E, Boström P, Seppänen M, Tammela T, Hellström P, Aaltomaa S, Leskinen M, Raitanen M, Kaasinen E; FinnBladder Group. Marttila T, et al. Eur Urol. 2016 Aug;70(2):341-7. doi: 10.1016/j.eururo.2016.03.034. Epub 2016 Apr 13. Eur Urol. 2016. PMID: 27085624 Clinical Trial.
Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.
Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E; Finnbladder Group. Rajala P, et al. J Urol. 2002 Sep;168(3):981-5. doi: 10.1016/S0022-5347(05)64556-9. J Urol. 2002. PMID: 12187204 Clinical Trial.
15 results